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Abstract
Purposes—Despite recommendations against prostate cancer screening with prostate-specific 
antigen (PSA) tests, about one-fourth of men age ≥40 years received PSA tests in 2015. This study 
aimed to answer 3 questions for men who had a PSA test in the past year: (1) What percentage of 
these men received the test first suggested by physicians? (2) What factors were associated with 
physician-initiated PSA testing (PIPT) versus patient/someone else-initiated testing? (3) What 
percentage of patients ever had shared decision-making when tests were initiated by physicians?
Methods—We analyzed the 2000 and 2015 National Health Interview Survey data. We 
calculated age-standardized prevalence of PIPT for both years. For 2015, we used logistic 
regression to calculate adjusted prevalence ratios for PIPT. We also calculated the prevalence of 
ever discussing both advantages and disadvantages.
Results—The age-standardized prevalence of PIPT was significantly higher in 2015 (84.9%) 
than in 2000 (72.3%). In 2015, nearly 90% of PSA screenings for men aged ≥70 years were 
suggested by physicians. PIPT was positively associated with 2 or more comorbid conditions and 
number of patient visits to the doctor. Less than one-third of men reported they had ever 
participated in a discussion of advantages and disadvantages of PSA testing.
Conclusions—The majority of men who had PSA testing in the past year reported that their 
physicians were the first to suggest testing, including men aged ≥70 years. Our study also points to 
the challenges and needs in conducting shared decision-making before PSA testing in clinical 
practice.
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Despite recommendations against prostate cancer screening with prostate-specific antigen 
(PSA) tests, approximately one-fourth of men age ≥40 years received PSA tests in 2015.1 
Many organizations, including the US Preventive Task Force (USPSTF), recommend that 
health care providers and their patients use shared decision-making (SDM), including 
discussion of benefits and harms of the test, before ordering it.1 This study aimed to answer 
3 questions for men who had a PSA test in the past year: (1) What percentage of these men 
received the test first suggested by physicians? (2) What factors were associated with 
physician-initiated PSA testing (PIPT) versus patient/ someone else-initiated testing? (3) 
What percentage of patients ever had SDM when tests were initiated by physicians?
Methods
We analyzed 2000 and 2015 National Health Interview Survey data. The overall National 
Health Interview Survey adult sample response rates were 72.1% (2000) and 55.2% (2015). 
Our analyses included male respondents aged ≥40 years who reported PSA testing as part of 
a routine examination in the past year and excluded men with PSA tests for other purposes 
or prostate cancer history. Our analyses included 1646 men from the year 2000 and 2024 
men from 2015. We calculated age-standardized prevalence of PIPT for both years. For 
2015, we used logistic regression to calculate adjusted prevalence ratios for PIPT. We also 
calculated the prevalence of ever discussing both advantages and disadvantages. We used 
SUDAAN 10 software (RTI International, Research Triangle Park, NC) to account for the 
sampling design.
Results
The age-standardized prevalence of PIPT was significantly higher in 2015 (84.9%) than in 
2000 (72.3%) (P <.01). In 2015, among men aged ≥70 years who received a PSA screening 
test, nearly 90% reported that it was first suggested by a physician (Table 1). PIPT was 
positively associated with 2 or more comorbid conditions and number of patient visits to the 
doctor, but inversely associated with prostate cancer family history (data not shown). Up to 
one-third of men who were screened reported that they had ever participated in a discussion 
of advantages and disadvantages of PSA testing (Table 2); SDM was slightly higher with 
PIPT (32% vs 25% for initiation by the patient/ someone else), but not significantly so (P =.
06).
Discussion
In 2000 and 2015, more than 70% of men who underwent PSA testing in the past year 
reported that their physicians were the first to suggest testing. Conflicting recommendations 
regarding PSA testing might have contributed to that high prevalence.1 Other factors might 
include physician beliefs about PSA screening effectiveness, perceived community standard 
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of care, and malpractice concerns.2 Medicare reimbursement for annual PSA testing might 
contribute to the willingness of physicians to propose or support testing.
PIPT is positively associated with 2 or more comorbid conditions and the number of patient 
encounters with clinicians. More patient encounters may increase a clinician’s opportunity 
to suggest the test. This study suggests that men with prostate cancer family history are more 
likely to first suggest PSA testing. In 2017, the US Preventive Task Force released draft 
recommendations, instead of against screening among men of all ages, calling for 
individualized decision making after discussion of potential benefits and harms of PSA 
testing among men aged 55 years to 69 years.3 In our study, more than two-thirds of men 
who were screened reported that they had never discussed advantages and disadvantages of 
PSA testing with physicians, a finding consistent with previous reports.4,5 These results 
point to the challenges and needs in conducting SDM in clinical practice.
Limitations of our study include self-reported data (which may be less accurate than medical 
records), results that may not be representative of nonrespondents, and lack of details on the 
relationship to the patient when “someone else requested the test.”
Acknowledgments
Funding: none.
References
1. Berkowitz Z, Li J, Richards TB, Marcus PM. Patterns of prostate-specific antigen test use for 
prostate cancer screening in the United States, 2005–2015. Am J Prev Med. 2017; 53:909–913. 
[PubMed: 29051016] 
2. Purvis Cooper C, Merritt TL, Ross LE, John LV, Jorgensen CM. To screen or not to screen, when 
clinical guidelines disagree: primary care physicians’ use of the PSA test. Prev Med. 2004; 38:182–
191. [PubMed: 14715210] 
3. Bibbins-Domingo K, Grossman DC, Curry SJ. The US Preventive Services Task Force 2017 draft 
recommendation statement on screening for prostate cancer: an invitation to review and comment. 
JAMA. 2017; 317:1949–1950. [PubMed: 28397958] 
4. Han PK, Kobrin S, Breen N, et al. National evidence on the use of shared decision making in 
prostate-specific antigen screening. Ann Fam Med. 2013; 11:306–14. [PubMed: 23835816] 
5. Li J, Berkowitz Z, Richards TB, Richardson LC. Shared decision making in prostate-specific 
antigen testing with men older than 70 years. J Am Board Fam Med. 2013; 26:401–8. [PubMed: 
23833155] 
Li et al. Page 3
J Am Board Fam Med. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Li et al. Page 4
Ta
bl
e 
1
A
ge
-S
ta
nd
ar
di
ze
d*
 
Pr
ev
al
en
ce
 o
f P
hy
sic
ia
n-
In
iti
at
ed
 P
ro
sta
te
-S
pe
ci
fic
 A
nt
ig
en
 T
es
tin
g 
by
 S
oc
io
de
m
og
ra
ph
ic
 a
nd
 S
cr
ee
ni
ng
-R
el
at
ed
 F
ac
to
rs
 A
m
on
g 
M
en
 
A
ge
d 
40
 Y
ea
rs
 a
n
d 
O
ld
er
 W
ho
 H
ad
 th
e 
Te
st
 in
 th
e 
Pa
st
 Y
ea
r,
 
N
at
io
na
l H
ea
lth
 In
te
rv
ie
w
 S
ur
ve
y,
 
20
00
 a
nd
 2
01
5
20
00
20
15
P 
v
a
lu
e‡
N
†
%
95
%
 C
I
N
†
%
95
%
 C
I
(20
15
 vs
 20
00
)
To
ta
l
16
42
72
.3
69
.0
75
.4
20
18
84
.9
82
.0
–8
7.
4
<
.0
1
A
ge
, c
ru
de
 e
st
im
at
es
 
40
 to
 5
4 
ye
ar
s
46
2
66
.1
60
.7
71
.1
38
0
83
.2
78
.2
–8
7.
2
<
.0
1
 
55
 to
 6
9 
ye
ar
s
70
7
76
.2
72
.4
79
.7
10
29
85
.5
82
.5
–8
8.
1
<
.0
1
 
70
+ 
ye
ar
s
47
3
85
.4
81
.2
88
.7
60
9
89
.3
85
.2
–9
2.
4
.
13
R
ac
e
 
W
hi
te
13
75
72
.9
69
.3
76
.2
16
92
84
.6
81
.4
–8
7.
3
<
.0
1
 
B
la
ck
18
9
72
.7
64
.3
79
.7
24
3
87
.3
79
.0
–9
2.
7
<
.0
1
 
O
th
er
s
78
71
.0
§
58
.6
80
.9
83
87
.1
75
.7
–9
3.
6
.
03
Et
hn
ic
ity
 
H
isp
an
ic
13
2
60
.9
51
.0
70
.0
14
0
85
.2
75
.3
–9
1.
5
<
.0
1
 
N
on
-H
isp
an
ic
15
10
73
.0
69
.5
76
.2
18
78
84
.9
81
.9
–8
7.
5
<
.0
1
R
eg
io
n
 
N
or
th
ea
st
32
5
76
.8
71
.0
81
.8
34
6
81
.7
72
.6
–8
8.
3
.
31
 
M
id
w
es
t
37
9
67
.5
61
.4
73
.1
44
1
86
.3
79
.2
–9
1.
2
<
.0
1
 
W
es
t
63
4
74
.0
67
.6
79
.4
74
5
86
.0
82
.1
–8
9.
2
<
.0
1
 
So
ut
h
30
4
70
.5
63
.0
77
.0
48
6
83
.8
76
.6
–8
9.
1
.
01
Bo
rn
 in
 U
ni
te
d 
St
at
es
 
Ye
s
14
89
73
.1
69
.6
76
.4
17
92
85
.7
82
.6
–8
8.
3
<
.0
1
 
N
o
14
6
62
.1
53
.1
70
.2
22
4
81
.7
73
.9
–8
7.
5
<
.0
1
Ed
uc
at
io
n
 
Le
ss
 th
an
 h
ig
h 
sc
ho
ol
27
3
63
.0
53
.9
71
.3
18
4
88
.8
§
74
.2
–9
5.
6
<
.0
1
 
H
ig
h 
sc
ho
ol
 g
ra
du
at
e
43
1
74
.7
67
.6
80
.6
48
3
83
.4
75
.3
–8
9.
2
.
07
 
So
m
e 
co
lle
ge
41
6
73
.6
68
.1
78
.5
55
4
85
.7
80
.1
–8
9.
9
<
.0
1
 
Co
lle
ge
 g
ra
du
at
e
51
0
69
.3
64
.1
74
.1
79
4
84
.3
79
.9
–8
8.
0
<
.0
1
J Am Board Fam Med. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Li et al. Page 5
20
00
20
15
P 
v
a
lu
e‡
N
†
%
95
%
 C
I
N
†
%
95
%
 C
I
(20
15
 vs
 20
00
)
M
ar
ita
l s
ta
tu
s
 
M
ar
rie
d 
or
 li
v
in
g 
w
ith
 p
ar
tn
er
11
55
71
.6
67
.9
75
.0
13
39
85
.2
82
.0
–8
8.
0
<
.0
1
 
W
id
ow
ed
, d
iv
o
rc
ed
, o
r s
ep
ar
at
ed
35
7
74
.5
66
.8
80
.9
50
3
81
.9
74
.3
–8
7.
7
.
13
 
N
ev
er
 m
ar
rie
d
12
6
75
.9
66
.4
83
.3
17
4
81
.1
70
.1
–8
8.
7
.
41
C
ur
re
n
tly
 e
m
pl
oy
ed
 
N
o
82
2
79
.2
71
.4
85
.3
10
67
90
.1
85
.9
–9
3.
2
.
01
 
Ye
s
82
0
69
.7
65
.4
73
.7
94
9
84
.0
80
.0
–8
7.
3
<
.0
1
Po
v
er
ty
 th
re
sh
ol
d,
 %
 
<
20
0
33
9
80
.0
70
.1
87
.2
37
8
87
.8
81
.8
–9
2.
0
.
12
 
20
0 
to
 2
99
28
3
68
.2
60
.5
75
.1
30
8
88
.5
79
.5
–9
3.
8
<
.0
1
 
30
0 
to
 3
99
21
9
74
.8
66
.9
81
.3
25
7
82
.3
72
.3
–8
9.
2
.
19
 
40
0 
to
 4
99
18
9
70
.8
62
.9
77
.7
22
9
82
.4
73
.3
–8
8.
8
.
03
 
50
0 
an
d 
m
or
e
61
2
69
.8
64
.8
74
.4
84
6
84
.5
80
.0
–8
8.
1
<
.0
1
U
su
al
 so
ur
ce
 o
f m
ed
ic
al
 c
ar
e
 
Ye
s
16
04
73
.0
69
.7
76
.1
19
71
85
.0
82
.0
–8
7.
5
<
.0
1
 
N
o
38
41
.9
§
27
.4
58
.0
46
81
.8
§
63
.3
–9
2.
1
<
.0
1
H
ea
lth
 in
su
ra
nc
e
 
U
ni
ns
ur
ed
/M
ed
ic
ai
d
10
6
82
.2
§
68
.7
90
.7
14
4
83
.6
73
.1
–9
0.
5
.
85
 
Pr
iv
at
e/
M
ili
ta
ry
/O
th
er
15
31
71
.9
68
.5
75
.1
18
69
85
.0
82
.0
–8
7.
5
<
.0
1
N
um
be
r 
of
 d
oc
to
r 
vi
sit
s i
n 
th
e p
as
t y
ea
r
 
1
24
2
71
.3
63
.8
77
.7
29
8
73
.1
64
.7
–8
0.
1
.
73
 
2
52
2
67
.1
61
.3
72
.4
68
1
86
.4
81
.9
–8
9.
9
<
.0
1
 
3+
87
8
76
.3
72
.1
80
.1
10
39
89
.4
85
.8
–9
2.
2
<
.0
1
Fa
m
ily
 h
ist
or
y 
of
 p
ro
st
at
e 
ca
nc
er
 
N
o
15
17
73
.2
69
.8
76
.3
18
06
87
.1
84
.6
–8
9.
2
<
.0
1
 
Ye
s
12
5
64
.8
55
.7
72
.9
21
2
68
.6
§
56
.9
–7
8.
2
.
59
C
an
ce
r, 
ex
cl
ud
in
g 
pr
o
st
at
e 
an
d 
no
nm
el
an
om
a 
sk
in
 
N
o
15
34
72
.2
69
.0
75
.2
18
20
85
.0
82
.0
–8
7.
5
<
.0
1
 
Ye
s
10
6
75
.0
§
58
.8
86
.3
19
7
83
.2
§
67
.1
–9
2.
3
.
39
J Am Board Fam Med. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Li et al. Page 6
20
00
20
15
P 
v
a
lu
e‡
N
†
%
95
%
 C
I
N
†
%
95
%
 C
I
(20
15
 vs
 20
00
)
C
om
or
bi
di
ty
||
 
N
on
e
13
26
71
.4
68
.1
74
.5
16
08
84
.9
81
.8
–8
7.
6
<
.0
1
 
1 
di
se
as
e
27
9
79
.7
70
.7
86
.5
33
9
81
.5
§
67
.0
–9
0.
5
.
80
 
2+
 d
ise
as
es
36
82
.9
§
67
.9
91
.8
71
97
.2
91
.1
–9
9.
2
.
02
R
ep
or
te
d 
he
al
th
 st
at
us
 
Ex
ce
lle
nt
/v
er
y 
go
od
90
0
72
.0
68
.0
75
.7
10
93
83
.8
79
.8
–8
7.
1
<
.0
1
 
G
oo
d/
fa
ir 
or
 p
oo
r
74
1
72
.1
66
.8
76
.8
92
5
86
.5
82
.8
–8
9.
5
<
.0
1
H
ad
 c
ol
or
ec
ta
l c
an
ce
r 
sc
re
en
in
g
 
Ye
s
80
5
72
.6
68
.7
76
.3
42
6
83
.4
78
.3
–8
7.
5
<
.0
1
 
N
o
82
4
70
.7
65
.3
75
.6
15
88
87
.7
84
.1
–9
0.
6
<
.0
1
*
R
es
ul
ts 
fo
r a
ll 
va
ria
bl
es
 ex
ce
pt
 a
ge
 w
er
e 
ag
e 
sta
nd
ar
di
ze
d 
to
 th
e 
ag
e 
di
str
ib
u
tio
n 
of
 th
e 
20
00
 st
an
da
rd
 p
op
ul
at
io
n.
† N
um
be
r m
ay
 d
iff
er
 fr
om
 1
64
6 
fo
r 2
00
0 
N
at
io
na
l H
ea
lth
 In
te
rv
iew
 S
ur
ve
y 
an
d 
20
24
 fo
r 2
01
5 
N
H
IS
 b
ec
au
se
 o
f “
do
n’
t k
no
w
,
”
 
re
fu
se
d,
 o
r m
iss
in
g 
re
sp
on
se
s.
‡ P
 
v
al
ue
 is
 c
al
cu
la
te
d 
by
 t 
te
st
 fr
om
 th
e 
co
nt
ra
st 
sta
te
m
en
t o
f P
RO
C 
D
ES
CR
IP
T 
pr
oc
ed
ur
e.
§ E
st
im
at
es
 m
ay
 n
ot
 b
e 
re
lia
bl
e 
as
 th
e 
co
nf
id
en
ce
 in
te
rv
al
 h
al
f w
id
th
 ≥
10
.
|| N
um
be
r o
f t
he
 fo
llo
w
in
g 
co
m
or
bi
di
tie
s (
no
ne
, 1
, 2
, a
nd
 m
ore
 di
sea
ses
): 
hy
pe
rte
ns
io
n,
 st
ro
ke
, 
di
ab
et
es
, c
hr
on
ic
 h
ea
rt,
 k
id
ne
y,
 
liv
er
,
 
an
d 
lu
ng
 d
ise
as
es
.
CI
, c
on
fid
en
tia
l i
nt
er
va
l.
J Am Board Fam Med. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Li et al. Page 7
Table 2
Prevalence of Ever Discussed Both Advantages and Disadvantages of Prostate-Specific Antigen Testing 
Among Men Aged 40 Years and Older Who Had the Test Within the Past Year, National Health Interview 
Survey, 2015
Ever Discussed Advantages and Disadvantages*
N† % 95% CI P value
Total 1955 31.0 28.1–34.1
Who first suggested the PSA test .061
 Patient or someone else 287 25.1 19.0–32.3
 Physician 1668 32.0 28.9–35.4
40 to 54 years 373 28.2 22.1–35.2
Who first suggested the PSA test .771
 Patient or someone else 74 26.2 14.6–42.5
 Physician 299 28.6 21.8–36.5
55 to 69 years 1003 34.8 30.8–39.1
Who first suggested the PSA test .006
 Patient or someone else 148 23.6 16.1–33.2
 Physician 855 36.8 32.4–41.3
70+ years 579 26.0 21.8–30.6
Who first suggested the PSA test .830
 Patient or someone else 65 27.3 16.0–42.6
 Physician 514 25.8 21.3–30.8
PSA, prostate-specific antigen testing; CI, confidential interval.
*Status of “Ever discussed advantages and disadvantages” was assessed based on two survey questions: (1) Did a doctor ever talk with you about 
the advantages of the test?; and (2) Did a doctor ever talk with you about the disadvantages of the test.
†Number may differ from the total of 2024 because of “don’t know,” refused, or missing responses.
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